Revlimid is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat multiple myeloma. Revlimid is often combined with a corticosteroid like dexamethasone to treat newly diagnosed myeloma. Revlimid is also known by its drug name, lenalidomide.
Revlimid is an immunomodulator — a drug that modulates the immune system. It is unknown how Revlimid works to fight myeloma, but it may prevent the growth of new blood vessels that supply tumors.
How do I take it?
Revlimid is taken orally on specific days in a 28-day cycle.
Revlimid comes in the form of a capsule.
The FDA-approved label for Revlimid lists common side effects including low blood cell counts, insomnia, dizziness, fever, fatigue, cough, rash, weakness, cold or flu symptoms, bronchitis, trouble breathing, back pain, muscle cramps, tremors, nausea, diarrhea, constipation, abdominal pain, and swelling in the extremities.
Rare but serious side effects listed for Revlimid include fetal harm in pregnant women, low blood count, liver failure, allergic reactions, tumor lysis syndrome, severe skin reactions, heart attack, stroke, dangerous blood clots, and other types of cancer.
For more details about this treatment, visit:
Revlimid — Celgene
Drug Therapy for Multiple Myeloma — American Cancer Society